Stockscreener 앱 받기
11.12
0.09%
0.010
시간 외 거래:
11.21
0.09
+0.81%
전일 마감가:
$11.11
열려 있는:
$11.27
하루 거래량:
2,757
Relative Volume:
0.37
시가총액:
$64.80M
수익:
$503.40K
순이익/손실:
$9.17M
주가수익비율:
6.1406
EPS:
1.8109
순현금흐름:
$-604.40K
1주 성능:
-3.30%
1개월 성능:
-9.67%
6개월 성능:
-6.40%
1년 성능:
+34.46%
1일 변동 폭
$11.12
$11.36
1주일 범위
$11.11
$11.80
52주 변동 폭
$7.10
$14.76
Daxor Corporation Stock (DXR) Company Profile
명칭
Daxor Corporation
전화
212-330-8500
주소
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
11.12 | 64.74M | 503.40K | 9.17M | -604.40K | 1.8109 |
|
ISRG
Intuitive Surgical Inc
|
479.93 | 169.66B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
156.53 | 44.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.01 | 36.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
43.59 | 34.30B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
227.41 | 33.20B | 5.40B | 1.49B | 1.78B | 10.12 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-16 | 개시 | Ascendiant Capital Markets | Buy |
Daxor Corporation 주식(DXR)의 최신 뉴스
Geopolitics Watch: What is the long term forecast for Daxor Corporation stockGDP Growth & Risk Controlled Swing Alerts - baoquankhu1.vn
Daxor Corporation to Showcase Next-Generation Portable - GlobeNewswire
Daxor to showcase next-gen portable BVA at ACC.26 session - TipRanks
Daxor (DXR) Showcases Innovative Blood Volume Analyzer at Major Cardiology Event - GuruFocus
Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26 - marketscreener.com
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - marketscreener.com
Blood volume test cut heart failure readmissions 56% in studies - Stock Titan
[N-CEN] DAXOR CORP SEC Filing - Stock Titan
Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha - MarketBeat
DXR: Direct blood volume analysis drives improved outcomes and rapid revenue growth in a vast market - TradingView
Daxor (DXR) Unveils Portable Blood Volume Analyzer at Critical C - GuruFocus
Daxor Corporation Showcases New Portable Blood Volume Analyzer - marketscreener.com
Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress - TipRanks
ICU blood volume test linked to 66% fewer deaths goes portable - Stock Titan
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewswire
Virtual investor conference to feature Daxor CEO’s 30-minute briefing - Stock Titan
Market Overview: Will Murano Global Investments Plc Equity Warrant benefit from rate cuts2026 Top Gainers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
What analyst consensus says on Daxor Corporation stockExit Point & Fast Moving Trade Plans - Naître et grandir
Layoff Watch: Is Daxor Corporation a turnaround storyGap Up & Safe Entry Trade Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Niagen Bioscience (NAGE), Daxor (DXR) - The Globe and Mail
European Stocks Set for Mixed Opening Amid Geopolitical Tensions - Intellectia AI
DXR SEC FilingsDAXOR CORP 10-K, 10-Q, 8-K Forms - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share - marketscreener.com
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Bitget
Daxor reports 45% revenue growth, plans regulatory shift - Investing.com
Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders - marketscreener.com
Daxor (DXR) Records Strong Growth and Regulatory Changes in 2025 - GuruFocus
Daxor issues update in Letter to Shareholders - TipRanks
Daxor (DXR) Secures FDA Clearance for Advanced Blood Volume Anal - GuruFocus
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - TradingView
7-pound blood volume analyzer wins FDA clearance, gains hospital users - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - marketscreener.com
Daxor Corporation Reports 2025 Fiscal Year Results: - GlobeNewswire
DXR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
FDA‑cleared BVA boosts momentum; Daxor (NASDAQ: DXR) posts NAV $9.07 and $46M operating valuation - Stock Titan
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0% - MarketBeat
Daxor Corporation (DXR) Competitors - Meyka
Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey - Defense World
EBIT per share of Daxor Corporation – NASDAQ:DXR - TradingView
Daxor (NYSEAMERICAN:DXR) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Daxor continues strategic expansion, opens new BVA program in Tennessee - TipRanks
Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and HealthStream (HSTM) - The Globe and Mail
Daxor (DXR) Expands BVA Program to Southern Middle Tennessee - GuruFocus
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - The Manila Times
Gainers Report: Will LightPath Technologies Inc benefit from government policy2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Is Daxor Corporation stock a safe haven assetWeekly Profit Summary & Stock Portfolio Risk Control - mfd.ru
Can Daxor Corporation stock double in next 5 yearsTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru
Daxor to shift regulatory reporting from Investment Company Act By Investing.com - Investing.com South Africa
Daxor Corporation (DXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.65%
자본화:
|
볼륨(24시간):